GSK: Protocol Summaries: Compounds

Quick Search

By Phase:

By Study Type:

By Population:

By Post Marketing Commitment:

By Status:

By Country:

GSK Study ID	Phase	Title	Status
ESS30008	phase 3	A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients.	Completed